09/01/2026
Dietitians Australia acknowledges today’s announcement to list Wegovy on the Pharmaceutical Benefits Scheme (PBS) for people living with established cardiovascular disease and obesity.
The PBAC has recommended that semaglutide be subsidised through the PBS for people who have already experienced a cardiovascular event such as a heart attack, stroke or have symptomatic peripheral arterial disease.
The recommendation determined that PBS funded access to the medicine will be limited to people with a BMI of 35 kg/m² or higher, or 32.5 kg/m² or higher for people of Asian, Aboriginal, or Torres Strait Islander ethnicity.
We welcome the acknowledgement by the PBAC on the need to improve access to non-pharmacological interventions, such as diet and physical activity support.
We know people can benefit significantly from GLP-1 medicines when they are appropriately prescribed and supported by a dietitian.
Wherever a prescription is given, access to evidence-based nutrition care must come with it before, during and after treatment to protect health and support sustainable outcomes.
Dietitians Australia continues to call for fair and equitable access to comprehensive multidisciplinary care for anyone prescribed weight loss medicines.
🔗 (PBAC) Meeting outcomes: https://bit.ly/4aVLDYy
🔗 Read out full statement: https://bit.ly/4qgcRO7